| __timestamp | Intra-Cellular Therapies, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 5496000 |
| Thursday, January 1, 2015 | 18187286 | 9786000 |
| Friday, January 1, 2016 | 24758063 | 6792000 |
| Sunday, January 1, 2017 | 23666957 | 7313000 |
| Monday, January 1, 2018 | 30099855 | 8382000 |
| Tuesday, January 1, 2019 | 64947625 | 10803000 |
| Wednesday, January 1, 2020 | 186363444 | 12944000 |
| Friday, January 1, 2021 | 272611040 | 21967000 |
| Saturday, January 1, 2022 | 358782000 | 32810000 |
| Sunday, January 1, 2023 | 409864000 | 46542000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biopharmaceuticals, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Xenon Pharmaceuticals Inc. over the past decade. From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. In contrast, Xenon Pharmaceuticals experienced a more modest rise, with expenses increasing by approximately 8.5 times over the same period.
This divergence highlights differing strategic priorities and operational scales. Intra-Cellular's aggressive expansion and marketing efforts are evident, while Xenon maintains a more conservative approach. These trends offer insights into each company's market positioning and future growth potential. As the biopharma sector continues to evolve, monitoring such financial metrics will be key for investors and industry analysts alike.
Breaking Down SG&A Expenses: argenx SE vs Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Merus N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Soleno Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Evotec SE: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.